Treatment Patterns of Patients With Multiple Myeloma in South Korea Using a Common Data Model

Speaker(s)

Jung E1, Suh HS2
1Department of Regulatory Science, Graduate School, Kyung Hee University, Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University, Seoul, South Korea, 2College of Pharmacy, Kyung Hee University, Department of Regulatory Science, Graduate School, Kyung Hee University, Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul, Korea, Republic of (South)

OBJECTIVES: This study investigates changes in treatment patterns for multiple myeloma before and after 2017, focusing on the impact of newly reimbursed therapies and updated treatment guidelines in South Korea, using the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).

METHODS: A retrospective cohort study was conducted using CDM data from approximately 2.8 million patients at Ajou University Hospital from 1993 to 2023. A total of 232 patients diagnosed with multiple myeloma during 2010 and 2023 were included. The baseline date was defined as the earliest diagnosis date, and patients were followed until censoring or death. Treatment patterns were analyzed, including the use of chemotherapeutic agents, immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies. Combination therapy was defined as treatments overlapping for more than 7 days. Treatment sequences were explored using a sunburst plot.

RESULTS: We identified 96 patients diagnosed with multiple myeloma before 2017 (mean age 69.0 years, 41.7% female) and 136 patients diagnosed after 2017 (mean age 66.94 years, 50.7% female). The most frequent first-line treatment before 2017 was a combination of an alkylating agent and steroid (32.6%), with melphalan and prednisolone being the most common individual agents (28.3%). After 2017, the most frequent first-line treatment was a combination of a proteasome inhibitor, an alkylating agent, and a steroid (32.6%), with melphalan, bortezomib, and prednisolone being the most common regimen (19.3%). A portion of patients transitioned to second-line therapy, with 68.7% before 2017 and 52.7% after 2017.

CONCLUSIONS: The treatment patterns for multiple myeloma have evolved, reflecting the impact of newly reimbursed therapies and updated treatment guidelines in South Korea since 2017. Continuous monitoring of treatment patterns is essential to optimize clinical practices and ensure the best care for patients with multiple myeloma in this evolving therapeutic landscape.

Code

HSD8

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology